July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Functional Analysis of the Complement Inhibitor Factor I in Sera of Patients with Advanced Age-Related Macular Degeneration
Author Affiliations & Notes
  • Peter Baciu
    Biology, Allergan, Inc, Irvine, California, United States
    Ocular Disease, Editas Medicine, Cambridge, Massachusetts, United States
  • Jae Yang
    Biology, Allergan, Inc, Irvine, California, United States
  • David Kavanagh
    National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospital, Newcastle upon Tyne, United Kingdom
  • John Atkinson
    Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States
  • Johanna Seddon
    Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, United States
    Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Peter Baciu, Allergan (E), Editas Medicine (E); Jae Yang, Allergan (E); David Kavanagh, None; John Atkinson, None; Johanna Seddon, Apellis (C), Gemini (S), THEA (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 790. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Baciu, Jae Yang, David Kavanagh, John Atkinson, Johanna Seddon; Functional Analysis of the Complement Inhibitor Factor I in Sera of Patients with Advanced Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):790.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Rare genetic variants in the complement alternative pathway regulator Factor I (FI) are associated with increased risk for developing advanced age-related macular degeneration (AAMD). Genetic screening frequently identifies variants of uncertain significance. To provide more insight into the function of these variants, we used an optimized biochemical assay of serum to identify both quantitative and qualitative FI deficiency in individuals with and without AAMD with and without rare FI variants.

Methods : FI activity was assessed in serum (0.2%, final conc) with 1.9 mM C3b and 290 nM factor-H followed by determinations of iC3b level using an ELISA with further confirmation by Western blot. Validation of the assay specificity was conducted by comparing results with samples in the presence and absence of exogenous C3b or serum. Each sample was assessed in at least two separate determinations.

Results : FI activity was determined in the serum of 119 individuals across 40 distinct rare FI variants and compared to the activity of FI in 94 wildtype controls. Presence of AAMD was 71% (n=84) within the population containing rare variants while 52% (n=49) had AAMD in the non-carrier (no FI rare variant) population. Analysis of individual variants identified two main categories of functional defect. Type 1 variants had a reduced FI serum level and reduced iC3b production in our assay which normalized when expressed per unit of FI. These variants (e.g. G119R, G287R) cause a quantitative deficiency of FI. Type 2 variants did not have low levels of FI but had reduced iC3b production which did not normalize when expressed per unit of FI. This second group is in keeping with a FI variant that is secreted but has decreased function (e.g. P553S).

Conclusions : We present a high throughput functional screening assay that detects impaired FI activity as a consequence of type 1 (impaired secretion) and type 2 (impaired functional activity) mutations. This assay may allow rapid stratification of patient populations in clinical trials ultimately leading to personalized patient care.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.